Home > Search Results: keywords:"societal perspective"
Search:
Search Tips :: Advanced Search
Search collections:
Sort by: Display results: Output format:
National Repository of Grey Literature 2 records found  Search took 0.01 seconds. 
Societal and governmental perspective of patients with Dravet syndrome and Lennox-Gastaut syndrome
 Krejčová, Martina ; Klimeš, Jiří (advisor) ; Grega, Dominik (referee)
Societal and governmental perspective of patients with Dravet syndrome and Lennox-Gastaut syndrome Author: Martina Krejčová Supervisor: PharmDr. Jiří Klimeš, Ph.D. Consultant: PharmDr. David Suchánek Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Králové, Charles University Introduction and aims: Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) are rare diseases. The orphan drug Epidyolex is indicated to reduce the frequency of seizures in these diseases. The aim of this work is to provide a comprehensive overview of orphan drug legislation and the potential of its reimbursement from health insurance and determine the costs of DS and LGS from a societal and governmental perspective. Methods: The data for the analysis is obtained from the questionnaire focused on the social benefit drawdown, increase in household costs, and loss of productivity of patients and their caregivers. Respondents are recruited in a cooperation with patient organisations and specialised centres. The costs from both perspectives are determined by adding the expenses of the health insurance company and the costs of lost productivity (societal perspective), or the costs to the social security system (governmental perspective). The human capital approach method (HCA) is used for the societal...
Detailed record
Societal and governmental perspective of patients with Dravet syndrome and Lennox-Gastaut syndrome
 Krejčová, Martina ; Klimeš, Jiří (advisor) ; Grega, Dominik (referee)
Societal and governmental perspective of patients with Dravet syndrome and Lennox-Gastaut syndrome Author: Martina Krejčová Supervisor: PharmDr. Jiří Klimeš, Ph.D. Consultant: PharmDr. David Suchánek Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Králové, Charles University Introduction and aims: Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) are rare diseases. The orphan drug Epidyolex is indicated to reduce the frequency of seizures in these diseases. The aim of this work is to provide a comprehensive overview of orphan drug legislation and the potential of its reimbursement from health insurance and determine the costs of DS and LGS from a societal and governmental perspective. Methods: The data for the analysis is obtained from the questionnaire focused on the social benefit drawdown, increase in household costs, and loss of productivity of patients and their caregivers. Respondents are recruited in a cooperation with patient organisations and specialised centres. The costs from both perspectives are determined by adding the expenses of the health insurance company and the costs of lost productivity (societal perspective), or the costs to the social security system (governmental perspective). The human capital approach method (HCA) is used for the societal...
Detailed record

Interested in being notified about new results for this query?
Subscribe to the RSS feed.
Digital Repository :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.2
Maintained by admin.invenio@techlib.cz
This site is also available in the following languages:
Česky  English